Airways delivery of rifampicin microparticles for the treatment of tuberculosis.
Airways delivery of rifampicin microparticles for the treatment of tuberculosis.
复制标题
DOI：
10.1093/jac/48.3.431
复制
发表时间：
2001-09
期刊：
影响因子：
--
通讯作者：
Sandra Suarez;Patrick O'Hara;M. Kazantseva;Christian E. Newcomer;Roy L. Hopfer;David N. McMurray;Anthony J. Hickey
中科院分区：
文献类型：
--
作者：
Sandra Suarez;Patrick O'Hara;M. Kazantseva;Christian E. Newcomer;Roy L. Hopfer;David N. McMurray;Anthony J. Hickey
采用结核分枝杆菌（H37Rv）感染的豚鼠模型，通过吹入（含乳糖赋形剂）或雾化的方式，筛选利福平单独、利福平在聚（丙交酯 - 乙交酯）微球（R - PLGA）内或单独的聚合物微粒（PLGA）向肺部的靶向递送情况。在感染后28天，与乳糖、PLGA或利福平治疗的动物相比，单次和两次剂量R - PLGA微球治疗的动物显示出活菌数量、炎症和肺损伤显著减少（P < 0.05）。两次剂量的R - PLGA导致脾脏肿大减轻。这些研究支持了R - PLGA递送至肺部治疗肺结核的潜力。
A Mycobacterium tuberculosis (H37Rv)-infected guinea pig model was used to screen for targeted delivery to the lungs by insufflation (with lactose excipient) or nebulization, of either rifampicin alone, rifampicin within poly(lactide-co-glycolide) microspheres (R-PLGA) or polymer microparticles alone (PLGA). Animals treated with single and double doses of R-PLGA microspheres exhibited significantly reduced numbers of viable bacteria, inflammation and lung damage compared with lactose-, PLGA- or rifampicin-treated animals 28 days post-infection (P < 0.05). Two doses of R-PLGA resulted in reduced splenic enlargement. These studies support the potential of R-PLGA delivered to the lung to treat pulmonary tuberculosis.